Imperial College London
Portrait Picture

Professor Shoumitro (Shoumi) Deb

Faculty of Medicine, Department of Brain Sciences

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 3313 4161s.deb CV

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Deb:2023:10.1192/bja.2022.61,
author = {Deb, S and Roy, M and Limbu, B},
doi = {10.1192/bja.2022.61},
journal = {BJPsych Advances},
pages = {322--333},
title = {Pharmacological management of psychopathology in people with intellectual disabilities and/or autism spectrum disorder},
url = {http://dx.doi.org/10.1192/bja.2022.61},
volume = {29},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - On average, 49–63% of people with intellectual disabilities and/or autism spectrum disorder (ASD) are prescribed psychotropic medications to treat psychopathology, including psychiatric illness, behaviours that challenge and the core symptoms and associated behaviours of these developmental disorders. In many cases, psychotropics, particularly antipsychotics, are used off-label without a proper indication, particularly to manage behaviours that challenge. The RCTs show moderate evidence supporting the efficacy of low-dose risperidone and some preliminary evidence for aripiprazole in treating behaviours that challenge among children with ASD and/or intellectual disabilities. The RCT-based evidence for the other psychotropics is equivocal, so no definitive conclusions can be made on their efficacy. Polypharmacy and the use of high doses of antipsychotics are prevalent in this population, leading to the risk of adverse events and drug–drug interactions. Despite various national and international guidelines, and government initiatives encouraging reduced psychotropic use, there is little evidence of this happening; on the contrary, the use of antidepressants, mood stabilisers and benzodiazepines may be increasing. A concerted multi-agency effort is urgently needed to address this significant public health concern of the overmedication of people with intellectual disabilities and/or ASD.
AU  - Deb,S
AU  - Roy,M
AU  - Limbu,B
DO  - 10.1192/bja.2022.61
EP  - 333
PY  - 2023///
SN  - 2056-4686
SP  - 322
TI  - Pharmacological management of psychopathology in people with intellectual disabilities and/or autism spectrum disorder
T2  - BJPsych Advances
UR  - http://dx.doi.org/10.1192/bja.2022.61
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863537200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.cambridge.org/core/journals/bjpsych-advances/article/pharmacological-management-of-psychopathology-in-people-with-intellectual-disabilities-andor-autism-spectrum-disorder/07027F4CEE8ACF844CF8503773623CF5
UR  - http://hdl.handle.net/10044/1/100482
VL  - 29
ER  -
Download